Hemophagocytic Lymphohistiocytosis Triggered by HSV‑1 in a Patient with Refractory Crohn’s Disease After Long‑Term Sequential Immunosuppressive Therapy Authors: Lingya Yao, Hanxiao Tu, Qian Cao Published: 2026 ABSTRACT AbstractHemophagocytic lymphohistiocytosis (HLH) is a rare syndrome of immune dysregulation. Here, we presented the case of a young male diagnosed with psoriasis and Crohn’s disease (CD), after multiple therapy failures, he started upadacitinib (UPA) in 2023. After induction and maintenance therapy, colonoscopy revealed suboptimal disease control. In November 2024, he was admitted to our hospital with fever and elevated liver enzymes, the final diagnosis was HSV-1-associated secondary HLH. After antiviral and hormonal treatment, the patient was discharged in stable condition. This case illustrates that HLH in such patients is rarely attributable to a single drug, rather, it results from the convergence of underlying CD, cumulative multi-agent immunosuppression, and an acute infectious trigger (HSV-1). Clinicians should maintain high vigilance for virus-associated HLH in heavily immunosuppressed IBD patients.Keywords: inflammatory bowel disease, hemophagocytic lymphohistiocytosis, herpes simplex virus, Jak kinase inhibitors Introduction Hemophagocytic lymphohistiocytosis (HLH) is a rare but life‑threatening syndrome of immune dysregulation characterized by excessive inflammation and multi‑organ failure.1 Patients with inflammatory bowel disease (IBD) have a higher baseline risk of HLH compared to the general population.2 Moreover, immunosuppressive agents used in IBD—particularly JAK inhibitors—can increase the risk of herpesvirus infections, which are common triggers for secondary HLH.3,4 Although a previous case of varicella‑zoster virus‑associated HLH during upadacitinib therapy for hidradenitis suppurativa has been reported,5 to our knowledge, no case of HSV‑1‑triggered HLH during upadacitinib treatment for Crohn’s disease has been described. This report fills that knowledge gap and highlights the multifactorial nature of HLH in this setting. Case Report A 27-year-old male presented with abdominal pain, diarrhea, oral ulcers, fever, and weight loss as initial symptoms and was diagnosed with Crohn’s disease (CD) with disease involvement in the small intestine, upper gastrointestinal tract, and perianal region at the age of 16. Considering the comorbid psoriasis, the first-line treatment was infliximab (IFX) combined with methotrexate (MTX). The patient achieved primary response to IFX and experienced a relatively stable period. However, at the age of 24, his disease recurred, manifesting as diarrhea, perianal pus discharge, and recurrence of skin lesions, suggesting secondary loss of response to IFX. Therefore, he underwent the incision and drainage of a complex high-level perianal abscess, excision of the primary lesion and hanging suture, debridement with excision of necrotic tissue from the anal skin and subcutis, anal dilatation and fistula resection. Subsequently, treatment was switched to adalimumab (ADA) combined with MTX. Unfortunately, as another anti-TNF agent, ADA still failed to halt the progression of both CD and psoriasis. Within less than one year of treatment, the patient developed intestinal stricture and suspected enteric fistulas. Surgical intervention was performed with laparoscopic partial small bowel resection and residual lesions remaining; therefore, treatment was switched to ustekinumab (UST) postoperatively. Similar to UST, subsequent dual-targeted therapies (gusechizumab combined with golimumab) also yielded suboptimal results. After failure of multiple first-line and second-line therapies for CD with comorbid psoriasis, the patient initiated treatment with the JAK1 inhibitor upadacitinib (UPA, 30mg once daily) in June 2023. After 3 months of induction therapy, colonoscopy reported an SES-CD score of 10, failing to meet either endoscopic response (criteria: ≥50% reduction from baseline SES-CD) or endoscopic remission (criteria: SES-CD≤2). Following 8 months of maintenance therapy, repeat colonoscopy showed improvement (SES-CD score of 6), but still did not achieve endoscopic response or remission, indicating suboptimal disease control. We recommended UPA combined with enteral nutrition, but the patient declined this regimen and opted to continue UPA (30 mg once daily) with irregular corticosteroid use instead. In November 2024, he was admitted to the emergency department with fever, intestinal obstruction-like symptoms (abdominal pain, bloating, vomiting, and cessation of flatus and defecation), and respiratory symptoms (sore throat, chest tightness, and cough). Laboratory findings revealed pancytopenia [white blood cell count: 0.9x10^9/L (ref: 3.5–9.5x10^9/L), hemoglobin: 67g/L (ref: 130–175g/L), platelet count: 44x10^9/L (ref: 125–350x10^9/L)] and markedly elevated liver enzymes [Alanine Aminotransferase: 3307U/L (ref: 9–50U/L), Aspartate Aminotransferase: 9172U/L (ref: 15–40U/L)]. Common causes of liver dysfunction (eg, drug toxicity, alcohol, hepatitis viruses, cytomegalovirus infection, Epstein-Barr virus infection, autoimmune hepatitis, ceruloplasmin abnormalities) were excluded. Further investigations revealed: hypofibrinogenemia (1.14 g/L, ref: 2.00–4.00 g/L), hyperferritinemia (42165.00 μg/L, ref: 30–400 μg/L), soluble CD25 (2391 pg/mL, ref: 0–6400 pg/mL), triglycerides (1.81mmol/L, ref: <1.7 mmol/L), lymph node ultrasound: enlarged left inguinal lymph nodes, bone marrow biopsy: hemophagocytosis (Figure 1). Based on the 2024 HLH diagnostic criteria,6 the patient met 5 out of 7 criteria, confirming the diagnosis of hemophagocytic lymphohistiocytosis (HLH). For the next etiological investigation, we focused on primary symptoms accompanied with fever. However, contrast-enhanced abdominal CT showed no evidence of intestinal infection or fistula, with only mildly active CD lesions—insufficient to explain the clinical presentation. Next, respiratory infection was suspected, and the peripheral blood MetaCAP (metagenomic next‑generation sequencing) returned positive for HSV‑1. No mucocutaneous herpetic lesions were observed. Serum HSV‑1 PCR was not performed due to technical constraints at admission. Finally, the diagnosis was confirmed: HSV-1-associated secondary HLH with refractory Crohn’s Disease. Hence, he was treated with acyclovir (440mg q8h ivgtt) for 7 days, ruxolitinib (10mg bid po) and intravenous dexamethasone (15mg qd) for 2 weeks. Ruxolitinib was chosen instead of etoposide because the patient had severe cytopenia and hepatic dysfunction, and the treating team preferred a JAK inhibitor with a more favourable safety profile in this critical setting.7 UPA was discontinued upon HLH diagnosis. Symptoms and laboratory parameters (cytopenias, ferritin, fibrinogen) gradually improved. He was discharged on ruxolitinib 5 mg bid and dexamethasone 7.5 mg daily, with stable follow‑up. Hemophagocytosis in bone marrow smear in secondary HLH: Hemophagocytosis is visible in the bone marrow, and the black arrows indicating phagocytosis. Discussion This case illustrates an episode of HSV‑1‑associated HLH occurring in a patient with longstanding, refractory CD who had been exposed to more than a decade of sequential immunosuppressive therapy, including anti‑TNF agents, anti‑IL‑12/23, anti‑IL‑23, methotrexate, and finally a JAK inhibitor (UPA). The importance of this case is not that UPA specifically caused HLH—such a causal link cannot be proven. Instead, it offers a valuable clinical lesson on how three coexisting factors may synergistically increase HLH risk: (1) the patient’s underlying Crohn’s disease, which confers a higher baseline risk of HLH;8 (2) cumulative multi‑agent immunosuppression over 11 years, which progressively impairs antiviral immunity; and (3) acute HSV‑1 infection as the direct trigger. The discussion in previous literature often addresses these factors separately, but their combination may create more than additive risk—a point that deserves emphasis. Studies supported that IBD patients on profound immunosuppression are particularly vulnerable to virus‑triggered HLH.9 JAK inhibitors, including upadacitinib, can suppress NK cell and CD8⁺ T‑cell function, potentially lowering the threshold for herpesvirus reactivation compared to some other agents.10,11 In our case, although upadacitinib was part of the regimen, it was not the sole or necessarily the primary culprit; the cumulative burden of prior agents and the patient’s active inflammatory state likely contributed substantially. Several limitations must be acknowledged. First, causality cannot be assigned to upadacitinib or any single agent—the HLH developed in a context of complex, long-standing immunosuppression. Second, the role of underlying CD itself as a contributing factor cannot be separated from drug effects. Third, this is a single case with limited generalizability. Fourth, we did not measure serial cytokine levels (eg, IFN‑γ, IL‑6, IL‑10, IL‑2R) due to clinical urgency, which could have provided additional supportive evidence. The term “MetaCAP” refers to metagenomic next-generation sequencing (mNGS) of peripheral blood, which identified HSV-1, however, HSV-1 PCR or viral load was not performed, and no mucocutaneous lesions were present, so the diagnosis relied on mNGS, which is a limitation. For treatment, we used ruxolitinib instead of etoposide because the patient had severe cytopenia and hepatic failure, making etoposide (with its myelosuppressive and hepatotoxic potential) less appealing. Ruxolitinib, a JAK1/2 inhibitor, has been used in secondary HLH with encouraging results12 and was considered safer in this context. Conclusion We report the first case of HSV-1-associated HLH in a Crohn’s disease patient receiving upadacitinib therapy. However, the true novelty lies not in the specific drug but in the complex interplay of long-standing CD, cumulative multi-agent immunosuppression, and an acute viral trigger. This case underscores that HLH in such patients should not be simplistically attributed to the most recently added agent; rather, it reflects a multifactorial process. Clinicians must remain vigilant for herpesvirus infections and HLH in heavily immunosuppressed IBD patients, and prompt recognition with appropriate antiviral and immunomodulatory therapy is crucial. Funding Statement This work was supported by National Key R&D Program of China (2023YFC2507300 to QC), Key-Area Research and Development Program of Guangdong Province (2023B1111040003 to QC). Ethics Statement The publication of the case details has been approved by the Ethics Committee of Sir Run Run Shaw Hospital, Zhejiang University School of Medicine (Approval NO: 2025-Yan-1021). Consent Statement Written informed consent for publication of their details was obtained from the patient. Author Contributions Lingya Yao, Hanxiao Tu and Qian Cao were participated in all works including study concept and design, acquisition of data, analysis and interpretation of data, drafting of the manuscript, critical revision of the manuscript for important intellectual content, and technical or material support. All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work. Disclosure The authors disclose no conflicts. References